GlassScriptPhysician profile
Anne Meade
NPI 1861809337
$1,538.09
in general payments reported to CMS, 2019-2025
21 companies · $17.57 in 2025
The $17.57 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,430 · 2022: $90.94 · 2025: $17.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $179.17 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $169.78 | 2021 | |
| Neos Therapeutics, LP | $167.00 | 2021 | |
| Abbvie INC. | $152.28 | 2021-2022 | |
| Eisai INC. | $112.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.29 | 2021 | |
| Sunovion Pharmaceuticals INC. | $75.60 | 2021 | |
| Adlon Therapeutics L.P. | $73.75 | 2021 | |
| Supernus Pharmaceuticals, INC. | $64.15 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $63.63 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $53.51 | 2021 | |
| Lundbeck LLC | $52.53 | 2021 | |
| Bausch Health US, LLC | $41.27 | 2021-2022 | |
| Alkermes, INC. | $40.05 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $39.35 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.50 | 2021 | |
| Novo Nordisk INC | $17.57 | 2025 | Ozempic, Rybelsus |
| Aytu Biopharma, INC. | $17.00 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.64 | 2022 | |
| Alfasigma USA, INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Meade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.